Premium
Integrin beta‐3 L33P: a new insight into the pathogenesis of chronic oxaliplatin‐induced peripheral neuropathy?
Author(s) -
Antonacopoulou A. G.,
Argyriou A. A.,
Scopa C. D.,
Kottorou A.,
Kominea A.,
Peroukides S.,
Kalofonos H. P.
Publication year - 2010
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2010.02966.x
Subject(s) - medicine , oxaliplatin , neurotoxicity , gastroenterology , peripheral neuropathy , pathogenesis , discontinuation , genotype , allele , colorectal cancer , chemotherapy , oncology , cancer , toxicity , endocrinology , gene , genetics , diabetes mellitus , biology
Aim: To assess the significance of the ITGB3 polymorphism at residue 33 (ITGB3 L33P) in the development of chronic oxaliplatin‐induced peripheral neuropathy (OXLIPN). Methods: Fifty‐five patients with advanced colorectal cancer were genotyped, using allele‐specific primers and sybr green in real‐time PCR. Patients had received adjuvant oxaliplatin‐based chemotherapy. The severity of the OXLIPN was defined by means of the clinical total neuropathy score (TNSc). Following the discontinuation of treatment, 34/55 patients (61.8%) developed OXLIPN. Grade I neurotoxicity was revealed in 13 (38.2%) patients and grade II neurotoxicity in 21 (61.8%) patients. Results: Patients without OXLIPN ( n = 21) were 19% homozygous for C, 33.3% were heterozygous, and 47.7% were homozygous for T. The corresponding percentages for patients developing any grade of OXLIPN ( n = 34) were similar. About half of patients (46.1%) with grade I OXLIPN were heterozygotes (CT), 23.1% were CC, and 30.8% were TT. The majority of patients with grade II OXLIPN were TT (66.7%) with the remaining 33.3% being CT. The TT genotype was associated with increased severity of OXLIPN compared to the genotypes containing the C allele ( P = 0.044). Conclusion: The ITGB3 L33P seems to be unrelated to the development of OXLIPN, but it appears to be related to its severity.